Posted 2nd October 2019 by Joshua Sewell
We’re looking back at the highlights from the Digital Pathology and AI meeting in 2018 as we anticipate this year’s Digital Pathology and AI Congress in December. This second post in our mini-series reviews Marylin Bui’s keynote presentation where she explained how the combination of Digital Pathology and Artificial Intelligence (AI) holds huge potential for patient care.
Posted 18th September 2019 by Joshua Sewell
I can recall clearly the pathologists coming to lecture our medical school class our second year in 1993.
Most of them felt compelled to tell us, “Pathology is a lot of fun, you can make a good living, but don’t go into it, there aren’t any jobs.”
Posted 9th September 2019 by Joshua Sewell
As Chief Data Officer for the OSTHUS Group, Eric Little co-founded LeapAnalysis, a new approach to AI, data integration and analytics.
LeapAnalysis is the first fully federated and virtualised search and analytics engine that runs on semantic metadata. It allows users to combine semantic models (ontologies) with machine learning algorithms to provide customers with unparalleled flexibility in utilizing their data.
Posted 2nd September 2019 by Joshua Sewell
The latest event in the Plant Genomics series provided two days of intriguing topics and case studies, not least concerning the ECJ ruling on gene editing and Machine Learning techniques in plant genomics. We have made the following presentation slides available from Ian Bancroft, Anna Coll, Aalt-Jan van Dijk, Nigel Halford, and Jurriaan Ton.
Posted 28th August 2019 by Jane Williams
Following the 5th Digital Pathology & AI Congress: USA, we have made the following presentation slides available from Iman Hajirasouliha, Kim Solez and Mrinal Mandal.
Posted 26th November 2018 by Jane Williams
The promise of an effective set of tools based on deep learning or other machine learning algorithms is the current buzz of the digital pathology markets. While the evolving tools, models and techniques are producing strongly positive results, there are still many factors which impact the utility and portability of models and tools being created across real-world data sets.
Human Genomic Evidence: Revolutionising the identification and prioritisation of targets for better medicines
Posted 17th October 2018 by Jane Williams
Nine out of 10 potential drugs that enter clinical trials never make it to the market. Failure often occurs because the biological target chosen is not well understood. However, it is hard to objectively select targets with a high chance of clinical success because the data required to predict efficacy and safety are complex, dispersed and incomplete. To address this challenge, Open Targets was founded in 2014 as a public-private partnership by GSK, EMBL-EBI and the Wellcome Sanger Institute. The consortium has grown since its launch, welcoming new partners Biogen in 2016, Takeda in 2017, and Celgene in 2018.
Posted 28th September 2018 by Jane Williams
When we last spoke, Brandon Allgood told us about The Future of AI. This week, we caught up with Brandon and spoke about drug discovery and machine learning algorithms.